Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 134-138, March 2010

Mammalian target of rapamycin: A new target in prostate cancer

Department of Urology, Derby City Hospital, Derby, United Kingdom

Received 30 January 2009; received in revised form 18 March 2009; accepted 19 March 2009. published online 15 June 2009.

Abstract 

Molecular targets in prostate cancer are continually being explored, especially in the poor-prognosis androgen-independent phase of the disease, for which there are currently few therapeutic options. One such target is the mammalian target of rapamycin (mTOR) protein. Activation of mTOR results in sequential activation of downstream molecules, which ultimately results in cell division. In this review, we consider the rationale for pursuing mTOR as a therapeutic target in prostate cancer and summarize preclinical and clinical studies of mTOR inhibition in prostate cancer.

Keywords: Rapamycin, mTOR, Prostate cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1078-1439(09)00097-0

doi:10.1016/j.urolonc.2009.03.023

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 134-138, March 2010